Why Benchmark Reagents Matter in Immunotherapy Development

Developing new immunotherapies requires more than demonstrating biological activity — it also requires comparison against well-characterized benchmark reagents with established functional activity.

A study published in the Journal for ImmunoTherapy of Cancer addressed this challenge while evaluating a novel CD40×HER2 bispecific antibody for HER2-positive gastric cancer. By comparing the investigational therapy directly against an agonistic anti-CD40 antibody, the researchers established whether the new molecule could achieve comparable immune activation while improving its safety profile.¹

Rather than evaluating the bispecific in isolation, the study demonstrated the value of using functional antibodies as trusted benchmark reagents during preclinical therapeutic development.

What Is an Agonistic Antibody?

Unlike blocking or depleting antibodies, agonistic antibodies activate their target receptor to stimulate a biological response. Agonistic anti-CD40 antibodies are widely used in preclinical immuno-oncology to activate antigen-presenting cells, enhance T-cell priming, and evaluate immune activation in mouse models.

The Challenge: Measuring a New Therapy Against an Established Standard

Novel immunotherapies are often designed to improve efficacy, reduce toxicity, or increase target specificity. Demonstrating those improvements requires comparison with a reference reagent whose biological activity has already been well characterized.

Without a reliable benchmark, it becomes difficult to determine whether differences in efficacy reflect true therapeutic improvement or simply differences in experimental conditions.

Functional in vivo antibodies provide researchers with consistent reference reagents that establish a reproducible baseline for evaluating new therapeutic candidates.

How Functional Antibodies Were Used

Researchers developed a CD40×HER2 bispecific antibody designed to localize CD40 activation within HER2-positive tumors while reducing the systemic immune activation associated with conventional CD40 agonists.

To evaluate its performance, the investigators compared the bispecific directly with an agonistic anti-CD40 antibody in a gastric cancer xenograft model. Both tumor growth and immune activation were assessed to determine whether the new molecule matched the biological activity of the established reference antibody while improving tolerability.¹

Using a well-characterized functional antibody provided a consistent benchmark against which the performance of the investigational therapy could be measured.

Key Findings

The comparison produced a clear result:

• An agonistic anti-CD40 antibody served as the reference standard for evaluating a novel CD40×HER2 bispecific antibody.¹
• The bispecific demonstrated antitumor activity comparable to the benchmark antibody.
• The investigational therapy achieved similar immune activation while reducing systemic toxicity observed with broad CD40 stimulation.
• The study highlights the importance of well-characterized functional antibodies as benchmark reagents during therapeutic development.

Featured Products

Bio X Cell Relevance

This study illustrates a role for functional antibodies that goes beyond direct therapeutic use: serving as trusted benchmark reagents. When evaluating new therapeutic candidates, researchers need confidence that comparisons are being made against a consistent, biologically validated standard — reliable benchmark antibodies help establish whether improvements in efficacy, safety, or target specificity represent genuine advances rather than experimental variability.

The agonistic anti-CD40 antibody used in this study is part of Bio X Cell's InVivoMAb™ platform, manufactured to deliver consistent biological activity across studies and manufacturing lots — the reproducibility needed to compare new therapeutic approaches against established standards with confidence.

References

1. Sun W, et al. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer. Journal for ImmunoTherapy of Cancer. 2022;10:e005063. https://doi.org/10.1136/jitc-2022-005063

Research Use Only